ICM
SPRO icon

Ionic Capital Management’s Spero Therapeutics SPRO Stock Holding History

Ionic Capital Management’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$458K Hold
195,939
– – 0.03% 89
2025
Q4 		$457K Sell
195,939
-12,786
-6% -$29.7K 0.06% 82
2025
Q3 		$392K Buy
208,725
+58,725
+39% +$129K 0.04% 97
2025
Q2 		$435K Buy
+150,000
New +$216K 0.12% 87

Other funds holding SPRO

GP
GSK plc London $599M AUM
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ionic Capital Management's SPRO Position: Q1 2026 in Review

Ionic Capital Management held its Spero Therapeutics (SPRO) position steady in Q1 2026 at 195,939 shares worth $458K. The position accounts for 0.03% of the portfolio, ranked #89.

Ionic Capital Management first reported a position in SPRO in Q2 2025 and has held it in 4 quarters since. 50 funds tracked by Wall St. Rank hold SPRO as of Q1 2026.

  • Ionic Capital Management held 195,939 shares of Spero Therapeutics worth $458K as of Q1 2026.
  • Ionic Capital Management left its Spero Therapeutics share count unchanged in Q1 2026.
  • Spero Therapeutics made up 0.03% of Ionic Capital Management's portfolio in Q1 2026, its #89 holding.
  • Ionic Capital Management first reported a position in Spero Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2026.

Based on Ionic Capital Management's 13F filing for Q1 2026, filed 15 May 2026.